Scarica l'app Stockscreener
10.60
7.59%
-0.87
Precedente Chiudi:
$11.47
Aprire:
$11.37
Volume 24 ore:
4.69M
Relative Volume:
0.80
Capitalizzazione di mercato:
$1.80B
Reddito:
$2.80M
Utile/perdita netta:
$-115.18M
Rapporto P/E:
-12.51
EPS:
-0.8473
Flusso di cassa netto:
$-94.03M
1 W Prestazione:
-8.78%
1M Prestazione:
+66.14%
6M Prestazione:
+217.84%
1 anno Prestazione:
+288.28%
Intervallo 1D:
$10.32
$11.41
Intervallo di 1 settimana:
$10.32
$12.00
Portata 52W:
$2.24
$12.05
Absci Corp Stock (ABSI) Company Profile
Nome
Absci Corp
Settore
Industria
Telefono
(360) 949-1041
Indirizzo
18105 SE MILL PLAIN BLVD, VANCOUVER
Compare ABSI vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
10.60 | 1.80B | 2.80M | -115.18M | -94.03M | -0.8473 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-02 | Iniziato | JP Morgan | Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-01-22 | Iniziato | Needham | Buy |
| 2024-10-02 | Iniziato | Guggenheim | Buy |
| 2024-07-03 | Iniziato | Morgan Stanley | Overweight |
| 2024-03-14 | Iniziato | Scotiabank | Sector Outperform |
| 2023-12-05 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2023-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Underweight |
| 2022-07-18 | Iniziato | Truist | Buy |
| 2022-03-02 | Ripresa | Cowen | Market Perform |
| 2022-02-01 | Iniziato | Berenberg | Buy |
| 2021-11-10 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-08-16 | Iniziato | BofA Securities | Neutral |
| 2021-08-16 | Iniziato | Cowen | Market Perform |
| 2021-08-16 | Iniziato | Credit Suisse | Outperform |
| 2021-08-16 | Iniziato | Stifel | Hold |
Mostra tutto
Absci Corp Borsa (ABSI) Ultime notizie
ABSI Stock Eyes Best Day Ever After Positive Hair Loss Drug Data, $100M Lilly-Backed Raise - Stocktwits
Pre-Market Movement | Absci's Put/Call Ratio Rises - 富途牛牛
Absci director Mary T Szela buys $148,866 in stock - Investing.com
Absci director Mary T Szela buys $148,866 in stock By Investing.com - Investing.com Nigeria
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $16 - 富途牛牛
Form 4 Absci Corp For: 6 July By Investing.com - Investing.com Nigeria
Absci (ABSI) director buys 12,900 shares in open-market trade - Stock Titan
ABSCI CORP (ABSI) soars 36.0%: Is further upside left in the stock? - MSN
ABSI Maintained by Truist Securities -- Price Target Raised to $17.00 - GuruFocus
Truist Financial Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $17 - 富途牛牛
Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy - Yahoo Finance
BTIG Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $13 - 富途牛牛
Absci Stock (ABSI) Opinions on Positive Phase 1 Data for ABS-201 - Moomoo
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program - Yahoo Finance
Absci (NASDAQ:ABSI) Rating Increased to Hold at Wall Street Zen - MarketBeat
Form 4 Absci Corp For: 26 June By Investing.com - Investing.com Australia
Absci (NASDAQ: ABSI) CEO has 59,896 shares withheld for RSU tax obligation - Stock Titan
Absci (ABSI) Is Up 37.8% After ABS-201 Data And Equity RaiseHas The Bull Case Changed? - Yahoo Finance
Absci Corporation (NASDAQ:ABSI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Absci Corp Company Profile & Introduction - Moomoo
Absci Corp : Morgan Stanley Raises Target Pri - Moomoo
H.C. Wainwright raises Absci stock price target on trial data By Investing.com - Investing.com South Africa
Guggenheim Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $15 - Moomoo
H.C. Wainwright raises Absci stock price target on trial data - Investing.com UK
Morgan Stanley Maintains Absci Corp(ABSI.US) With Hold Rating, Raises Target Price to $10.08 - Moomoo
A Quick Look at Today's Ratings for Absci Corp(ABSI.US), With a Forecast Between $11 to $16 - Moomoo
ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study - TradingView
ABSI Forecast — Price Target — Prediction for 2027 - TradingView
Absci Corporation Stock 12‑Month Price Target Raised to $12, Implies 19% Upside - TradingView
ABSI Maintained by HC Wainwright & Co. -- Price Target Raised to $16.00 - GuruFocus
Absci Corporation Stock 12‑Month Price Target Raised to $11.2, Implies 11% Upside - TradingView
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock? - Yahoo Finance
Tracking Cathie Wood: Major AI Biotech Discovery Bet on Recursion, Heavy Reduction in Absci Holdings - Moomoo
Cathie Wood's investment moves on June 24! Significant increase in holdings of Recursion, an AI-driven drug discovery company; sold over 670,000 shares of Absci - Moomoo
United StatesGoodwin Guides Absci On Pricing Of $100 Million Underwritten Offering - Mondaq
Why Did UAL, GLW, ABSI Stocks Surge To 52-Week Highs Today? - TradingView
Absci (ABSI) Is Up 40.3% After Positive ABS-201 Data And Equity Raise Has The Bull Case Changed? - simplywall.st
Biopharma bites: Remix's reverse merger, Absci's raise, ADC's layoffs, and a new R&D head for Lundbeck - FirstWord Pharma
ABSI stock eyes best day ever after positive hair loss drug data, $100M Lilly-backed raise - MSN
ABSI Reiterated by Needham -- Price Target Raised to $11.00 - GuruFocus
Form 424B5 Absci Corp For: 24 June By Investing.com - Investing.com Nigeria
Absci Announces $100 Million Public Equity Offering - TipRanks
Absci (NASDAQ: ABSI) sells 13.5M shares at $7.41; Eli Lilly buys 5.4M - Stock Titan
Absci Corp Azioni (ABSI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Absci Corp Azioni (ABSI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pangalos Menelas N | Director |
May 13 '26 |
Buy |
5.36 |
37,453 |
200,748 |
232,308 |
| Busch Andreas | Chief Innovation Officer |
Mar 12 '26 |
Buy |
2.29 |
100,000 |
229,000 |
421,446 |
| Pangalos Menelas N | Director |
Feb 27 '26 |
Buy |
2.74 |
75,095 |
205,760 |
189,055 |
| McClain Sean | Chief Executive Officer |
Feb 23 '26 |
Option Exercise |
1.21 |
396,399 |
479,643 |
8,730,966 |
| McClain Sean | Chief Executive Officer |
Feb 02 '26 |
Sale |
2.99 |
26,761 |
80,015 |
8,334,567 |
| Jonasson Zachariah | CFO / CBO |
Feb 02 '26 |
Sale |
2.99 |
17,496 |
52,313 |
383,538 |
| VAN HOUTEN FRANS | Director |
Dec 05 '25 |
Buy |
3.72 |
40,000 |
148,800 |
63,320 |
| Pangalos Menelas N | Director |
Sep 22 '25 |
Buy |
2.66 |
95,785 |
254,788 |
113,960 |
| Bedrick Todd | SVP, CAO |
Sep 22 '25 |
Buy |
2.70 |
10,000 |
27,000 |
180,428 |
| Busch Andreas | Chief Innovation Officer |
Jul 28 '25 |
Buy |
3.04 |
50,000 |
152,000 |
327,264 |
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):